NCT00313482View on ClinicalTrials.gov

PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC

PHASE2TerminatedINTERVENTIONAL

Enrollment

35

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions

Hormone Refractory Prostate Cancer

Interventions

DRUG

Sargramostim

250 mcg/m2 SC days 2-15 of each cycle

DRUG

Docetaxel

75 mg/m2 IV over 1 hour on Day 1 of each cycle

DRUG

Prednisone

5 mg orally BID on Day 1 continuously

Trial Locations (1)

43215

Veeda Oncology, Columbus

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Bayer

INDUSTRY

lead

Veeda Oncology

OTHER